Clinical trials: Intravenous
Acute Exacerbation of Remitting Relapsing Multiple Sclerosis, Clinically Isolated Syndrome
Nanocort in Acute Exacerbation of Relapsing-Remitting Multiple Sclerosis (MS)
Patients with an acute exacerbation of Relapsing-Remitting Multiple Sclerosis or with Clinically Isolated Syndrome receive either one single infusion of Nanocort or three daily infusions of SoluMedrol.
- Trial name
- NCT01039103
- Testing
- PEG-liposomal prednisolone sodium phosphate, Methylprednisolone
- Where
- 8 sites in Belgium, Germany and 1 more
- Volunteers
- 15 people
- Sponsor
- Lakefront Biotherapeutics NV
Phenylketonuria
A Phase 1/Phase 2 Open-label Study to Evaluate the Safety, Tolerability, and Efficacy of a Single Intravenous Administration of SAR444836 in Adult Participants With Phenylketonuria
This is a single group Phase 1/Phase 2, 1-arm, open-label study with SAR444836, an adeno-associated virus (AAV) vector-mediated gene transfer of human phenylalanine hydroxylase (PAH), for the treatment of adult participants with…
- Trial name
- NCT05972629
- Testing
- SAR444836
- Where
- 11 sites in United States, Argentina and 3 more
- Volunteers
- 32 people
- Sponsor
- Sanofi
Healthy Subjects
Pharmacokinetics and Bioavailability of Single Subcutaneous Doses of Methylnaltrexone Versus Intravenous Dose
This is an open-label, Phase I study. Study treatments will entail a four-way crossover among three single, ascending, subcutaneous doses and one intravenous dose of MNTX in six healthy normal male volunteers.
- Trial name
- NCT01367496
- Testing
- SC Methylnaltrexone (MNTX), IV Methylnaltrexone (MNTX)
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Bausch Health Americas, Inc.
Covid19
Study of Intravenous COVI-MSC for Treatment of COVID-19-Induced Acute Respiratory Distress
This is a Phase 2 randomized controlled study to assess the safety and efficacy of COVI-MSC in the setting of current standard of care treatments for COVID-19 infection in hospitalized subjects with acute respiratory distress…
- Trial name
- NCT04903327
- Testing
- COVI-MSC
- Where
- 6 sites in Brazil
- Volunteers
- 43 people
- Sponsor
- Sorrento Therapeutics, Inc.
Candidemia, Mycoses
CD101 Compared to Caspofungin Followed by Oral Step Down in Subjects With Candidemia and/or Invasive Candidiasis-Bridging Extension
The purpose of this study is to determine if intravenous CD101 is safe and effective in the treatment of candidemia and/or invasive candidiasis when compared to caspofungin (followed by oral fluconazole).
- Conditions
- Candidemia, Mycoses, Fungal Infection, Fungemia
- Trial name
- STRIVE (NCT02734862)
- Testing
- CD101, Caspofungin, Fluconazole
- Where
- 63 sites in United States, Belgium and 8 more
- Volunteers
- 207 people
- Sponsor
- Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Healthy Volunteers (HV)
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of KR25102 in Healthy Volunteers
Phase 1 Single Ascending Doses(SAD): Six cohorts of 53 healthy volunteers (HVs) will receive a single IV bolus injection of study drug or placebo.
- Trial name
- NCT07618156
- Testing
- KR25102 for Injection
- Where
- China
- Volunteers
- 83 people, healthy volunteers welcome
- Sponsor
- Jiangxi Kvvit Pharmaceutical Co., Ltd.
Healthy Subjects
A Study in Healthy Volunteers to Investigate How Much Test Medicine [14C]-Uproleselan is Taken up by the Body When Administered Directly Into the Vein (IV)
The purpose of the study is to measure how the radiolabelled test medicine [14C]-Uproleselan (GMI-1271) is taken up, broken down and removed from the body when given intravenously (into a vein) in a group of 6 males.
- Trial name
- NCT03606447
- Testing
- Uproleselan
- Where
- United Kingdom
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- GlycoMimetics Incorporated
Diabetes, Diabetes Mellitus, Type 1
Comparing Insulin Aspart With Fast-acting Insulin Human in Subjects With Type 1 Diabetes
This trial is conducted in Japan. The aim of the trial is to compare pharmacokinetics (at which rate the body eliminates the substance from the body) of insulin aspart with fast-acting insulin human following intravenous (IV)…
- Trial name
- NCT01269606
- Testing
- insulin aspart, insulin human
- Where
- Japan
- Volunteers
- 13 people
- Sponsor
- Novo Nordisk A/S
Major Advanced Solid Tumors Other Than Colorectal
Study of PM01183 in Non-Colorectal Cancer Patients as a Days 1 and 8 Intravenous Short Infusion Every 3 Weeks
Phase I Study of PM01183 in Non-Colorectal Cancer Patients to determine the recommended dose (RD) of PM01183.
- Trial name
- NCT01405391
- Testing
- PM01183
- Where
- 2 sites in United States
- Volunteers
- 42 people
- Sponsor
- PharmaMar
Alzheimer's Disease (AD)
VY7523-102: Randomized, Placebo-Controlled, Double-Blind, Multiple Ascending Dose Study in Participants With Early Alzheimer's Disease
This study is to be conducted in participants with early Alzheimer's Disease to test VY7523, a new drug being researched for treatment of Alzheimer's Disease.
- Trial name
- NCT06874621
- Testing
- VY7523
- Where
- 23 sites in United States, Canada
- Volunteers
- 52 people
- Sponsor
- Voyager Therapeutics
Multiple Sclerosis
Multi-Center Study Safety of Adipose Derived Mesenchymal Stem Cells for the Treatment of Multiple Sclerosis
The intent of this clinical study is to answer the questions: 1) is the proposed treatment safe and 2) is treatment effective in improving the disease pathology of patients with Multiple Sclerosis and clinical outcomes.
- Trial name
- NCT02326935
- Testing
- Autologous adipose derived mesenchymal cells
- Where
- Cayman Islands
- Volunteers
- 2 people
- Sponsor
- American CryoStem Corporation
Advanced Cancer, Brain Involvement
Study of 4-Demethylcholesteryloxycarbonylpenclomedine (DM-CHOC-PEN) in Patients With Advanced Cancer
DM-CHOC-PEN is a polychlorinated pyridine cholesteryl carbonate that has demonstrated antineoplastic activities in human xenograft intracerebrally implanted tumor mouse models, acceptable preclinical toxicities in mouse, rat and…
- Trial name
- DM-CHOC-PEN (NCT01048008)
- Testing
- DM-CHOC-PEN
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- DEKK-TEC, Inc.
Lymphoma, Non-Hodgkin, Multiple Myeloma
A Safety and Efficacy Study of CNTO 328 in Patients With B-Cell Non-Hodgkin's Lymphoma, Multiple Myeloma, or Castleman's Disease
The purpose of this study is to evaluate of the study of different CNTO 328 doses and schedules and to see if CNTO 328 has any effect on Non-hodgkin's Lymphoma, Multiple Myeloma or Castleman's disease.
- Conditions
- Lymphoma, Non-Hodgkin, Multiple Myeloma, Giant Lymph Node Hyperplasia
- Trial name
- NCT00412321
- Testing
- CNTO 328
- Where
- 9 sites in United States
- Volunteers
- 67 people
- Sponsor
- Centocor, Inc.
Rheumatoid Arthritis
Study of NI-071 in Comparison With Remicade in Patients With Rheumatoid Arthritis
The purpose of this study is to compare the safety of NI-071 with Remicade® (infliximab) in patients with Rheumatoid Arthritis inadequately treated with Methotrexate.
- Trial name
- NCT01567358
- Testing
- Infliximab
- Where
- Japan
- Volunteers
- 14 people
- Sponsor
- Nichi-Iko Pharmaceutical Co., Ltd.
Primary Immune Deficiency Disorders (PIDD)
Open Label, Phase III Study of NABI-IGIV 10% [Immune Globulin Intravenous(Human), 10%] In Subjects With Primary Immune Deficiency Disorders (PIDD)
The purpose of this study is to determine if NABI-IGIV (10%) [Immune Globulin Intravenous (Human), 10%] is safe and effective in preventing serious bacterial infections (SBIs) in the treatment of patients with primary immune…
- Trial name
- NCT00538915
- Testing
- Nabi-IGIV 10% [Immune Globulin Intravenous (Human). 10%]
- Where
- 17 sites in United States
- Volunteers
- 63 people
- Sponsor
- ADMA Biologics, Inc.
Anemia in Pre-Dialysis Patients
Clinical Study of R744 to Predialysis Patients
This study will assess the efficacy and safety of subcutaneous or intravenous R744 in renal anemia patients on Predialysis.
- Trial name
- NCT00433615
- Testing
- R744
- Where
- 6 sites in Japan
- Volunteers
- 124 people
- Sponsor
- Chugai Pharmaceutical
Chemotherapy-Induced Nausea and Vomiting
A Safety Study of Intravenous Pro-Netupitant and Palonosetron Combination for the Prevention of Nausea and Vomiting
NEPA-15-18 is a clinical study assessing safety of pro-netupitant and palonosetron, two antiemetic drugs, given with oral dexamethasone.
- Trial name
- NCT02517021
- Testing
- Pro-netupitant/Palonosetron, Netupitant/Palonosetron, Dexamethasone
- Where
- 74 sites in United States, Austria and 10 more
- Volunteers
- 405 people
- Sponsor
- Helsinn Healthcare SA
Bladder Cancer, Breast Cancer
A Study Comparing Oral Picoplatin With Intravenous Picoplatin in Subjects With Solid Tumors
Picoplatin is a new platinum-based chemotherapy drug that has been studied in a variety of cancers. Phase 1 and 2 studies have demonstrated that picoplatin may be effective in patients whose cancer returns or does not improve…
- Conditions
- Bladder Cancer, Breast Cancer, Colorectal Cancer, Gastrointestinal Neoplasm
- Trial name
- NCT00465725
- Testing
- Picoplatin
- Where
- 3 sites in United States
- Volunteers
- 18 people
- Sponsor
- Poniard Pharmaceuticals
Solid Tumors
Dose Escalation Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intravenous ALN-VSP02 In Patients With Advanced Solid Tumors With Liver Involvement
The purpose of the study is to determine the safety, tolerability, pharmacokinetics, and pharmacodynamics of intravenous ALN-VSP02, an RNAi therapeutic, in patients with advanced solid tumors with liver involvement.
- Trial name
- NCT00882180
- Testing
- ALN-VSP02
- Where
- 10 sites in United States, Spain
- Volunteers
- 41 people
- Sponsor
- Alnylam Pharmaceuticals
Fabry Disease
Extension Study of PRX-102 for up to 60 Months
To evaluate the ongoing safety, tolerability, and efficacy parameters of PRX-102 in adult Fabry patients who have successfully completed treatment with PRX-102 in studies PB-102-F01 and PB-102-F02.
- Trial name
- NCT01981720
- Testing
- PRX-102 (pegunigalsidase alfa)
- Where
- 8 sites in United States, Paraguay and 2 more
- Volunteers
- 15 people
- Sponsor
- Protalix
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.